Phase I Randomized, Open-label, Parallel-controlled, Pharmacokinetic and Safety Study of BR201 Injection Versus Cosentyx in Healthy Male Subjects

NCT06126718 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

88

Enrollment

INDUSTRY

Sponsor class

Conditions

Psoriasis

Interventions

DRUG: BR201
DRUG: Cosentyx（Secukinumab ）

Sponsor

BioRay Pharmaceutical Co., Ltd.